More than 50 percent of biopharmaceutical companies are adversely affected by manufacturing bottlenecks due to capacity and production purification problems
These new environmentally friendly chromatography sorbents improve efficiency and economics of drug manufacturing, says Pall.
More than 50 percent of biopharmaceutical companies are adversely affected by manufacturing bottlenecks due to capacity and production purification problems.
Compounding this challenge is the increasingly global demand for new protein-based drugs.
To help overcome these production bottlenecks, Pall is launching two new chromatography sorbents that provide a novel approach to protein purification.
